The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To characterize the safety profile of MDL 28574A following both acute and subchronic dosing in HIV-positive patients. To determine the MTD of both acute and subchronic doses of this drug when administered as oral solution. To determine the pharmacokinetic profile of MDL 28574A and castanospermine (from which MDL 28574A is derived) following both acute and subchronic dosing.
Condition or disease
Drug: Celgosivir hydrochloride
In Part A of the study, patients receive a single oral dose of MDL 28574A on day 1 and are followed through day 7. In Part B, patients receive single daily doses of the drug on days 1 through 14 and are followed through day 21.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 50 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
CD4 count >= 500 cells/mm3.
No evidence of AIDS.
No antiretroviral therapy within 30 days prior to study entry.
Presence of lymphadenopathy in two or more extrainguinal sites, at least 1 cm in diameter for 3 or more months, is permitted.
Patients with the following symptoms or conditions are excluded:
Clinically significant abnormalities on routine hematology (other than CD4 count and Western blot), serum chemistry, and urinalysis.
Positive stool guaiac.
Abnormal medical history or physical exam including temperature, heart rate, and blood pressure.
Clinically significant organ abnormality or disease.
Positive urine drug screen for illicit drugs.
Inability to comply with study procedures.
Routine treatment with nonprescription medications.
Treatment with other medications except with approval of the investigator.
Patients with the following prior conditions are excluded:
Prior participation in this trial.
Serious physical or mental illness within 1 year prior to study entry that would confound interpretation of data.
Antiretroviral therapy within 30 days prior to study entry.
Known medications that alter renal, hepatic, or hematologic/immunologic function (such as barbiturates, phenothiazines, cimetidine, and immunomodulators) within 14 days prior to study entry.
Routine treatment with nonprescription medications within 3 days prior to study entry.
History of alcohol or drug abuse within the past year.